冠状病毒感染和阿尔茨海默病之间的共同分子特征揭示了药物开发的目标
Morteza Abyadeh1, Vijay K Yadav2, Alaattin Kaya1
1Department of Biology, Virginia Common wealth University, Richmond, VA, USA.
Journal of Alzheimer's disease : JAD
|August 28, 2023
概括
COVID-19感染和阿尔茨海默氏病 (AD) 具有共同的分子通路,包括改变的cAMP信号和神经炎症. 识别这些共同的机制和遗传点可能有助于预防COVID-19患者的认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 传染性疾病 传染性疾病
背景情况:
- 认知能力下降是COVID-19的常见结果之一.
- 新出现的证据表明,COVID-19和阿尔茨海默病 (AD) 之间存在联系.
- 将COVID-19与AD联系在一起的精确分子机制在很大程度上是未知的.
研究的目的:
- 阐明COVID-19和AD之间的关联背后的分子机制.
- 确定针对COVID-19相关神经疾病的药物干预的潜在遗传标.
主要方法:
- 分析了来自638个大脑样本的转录组数据集.
- 使用了强大的排名聚合,功能丰富和网络分析.
- 在AD和COVID-19大脑中确定了常见的改变基因,miRNA和转录因子.
主要成果:
- 在AD和COVID-19大脑中常见的改变途径包括下调的循环腺单酸盐 (cAMP) 信号和牛代谢.
- 在这两种条件下,神经炎症通路都被发现是上调的.
- 基因-miRNA和基因转录因子网络揭示了潜在的调节机制.
结论:
- 共享途径的改变,包括减少cAMP信号和增加神经炎症,可能会增加COVID-19患者对认知衰退和AD的易感性.
- 鉴定出基因标为制药战略提供了潜在的潜力,以减轻与COVID-19和AD相关的神经风险.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212